Acadia Pharmaceuticals (ACAD) Shares Outstanding (Diluted Average) (2010 - 2026)

Acadia Pharmaceuticals' Shares Outstanding (Diluted Average) history runs 10 years deep, the most recent figure standing at $172.7 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Diluted Average) rose 3.0% year-over-year to $172.7 million; the TTM figure through Mar 2026 stood at $172.7 million (up 3.0% YoY), while the FY2025 annual figure was $169.9 million, up 2.14% from the prior year.
• Shares Outstanding (Diluted Average) was $172.7 million for Q1 2026 at Acadia Pharmaceuticals, up from $169.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $172.7 million in Q1 2026 to a low of $161443.0 in Q2 2022.
• Historically, Shares Outstanding (Diluted Average) has averaged $127.0 million across 5 years, with a median of $164.2 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Diluted Average) jumped 102131.75% in 2023, then sank 99.9% in 2024.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $161.7 million in 2022, then gained by 1.32% to $163.8 million in 2023, then gained by 1.55% to $166.4 million in 2024, then advanced by 2.14% to $169.9 million in 2025, then climbed by 1.64% to $172.7 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $172.7 million (Q1 2026), $169.9 million (Q4 2025), and $170.6 million (Q3 2025), per Business Quant data.